The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice

Journal of Alzheimer's Disease

Volumn 24, Issue 4, 2011, Pages 799-816

  Balducci, Claudia ^a   Mehdawy, Bisan ^b   Mare, Lydia ^a   Giuliani, Alessandro ^c   Lorenzini, Luca ^c   Sivilia, Sandra ^c   Giardino, Luciana ^c   Calzà, Laura ^c   Lanzillotta, Annamaria ^d   Sarnico, Ilenia ^d   Pizzi, Marina ^d,k   Usiello, Alessandro ^e   Viscomi, Arturo R ^f   Ottonello, Simone ^f   Villetti, Gino ^g   Imbimbo, Bruno P ^g   Nisticò, Giuseppe ^h   Forloni, Gianluigi ^a   Nisticò, Robert ^i,j  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

^g CHIESI FARMACEUTICI S P A   (Italy)

^h EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

ⁱ UNIVERSITY OF CALABRIA   (Italy)

^j IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^k IRCCS SAN CAMILLO HOSPITAL   (Italy)

more..

Author keywords

Alzheimer's disease; amyloid ; fear conditioning; long term potentiation; non steroidal anti inflammatory drugs; recognition memory; secretase modulators

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHF 5074; GAMMA SECRETASE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; CONVALESCENCE; DRUG BLOOD LEVEL; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; LONG TERM MEMORY; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

EID: 79959222583     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101839     Document Type: Article

References (52)

1. Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, Fontanella L, Misiano P, Bigogno C, Rizzi A, Riccardi B, Biscaioli M, Marchetti S, Puccini P, Catinella S, Rondelli I, Cenacchi V, Bolzoni PT, Caruso P, Villetti G, Facchinetti F, Del Giudice E, Moretto N, Imbimbo BP (2005) Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of-amyloid1-42 secretion. J Med Chem 48, 5705-5720. (Pubitemid 41298345)
2. Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, Riccardi B, Puccini P, Moretto N, Grassi F, Ottonello S, Leon A (2007) In vitro and in vivo profiling of CHF5022 and CHF5074 two-amyloid1-42 lowering agents. Pharmacol Res 55, 318-328. (Pubitemid 46533934)
3. Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimers disease. Br J Pharmacol 156, 982-993.
4. Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V, Del Giudice E, DArrigo A, Leon A, Villetti G, Calzá L (2010) CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimers disease. J Alzheimers Dis 20, 159-173.
5. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in non-transgenic human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058. (Pubitemid 30365675)
6. Van Dam D, DHooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17, 388-396. (Pubitemid 36459519)
7. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimers disease. Proc Natl Acad Sci U S A 103, 5161-5166.
8. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010) Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimers disease. Acta Neuropathol 119, 523-541.
9. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, Wang Q, Xu H, Wang JZ (2006) Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 98, 1167-1175. (Pubitemid 44127792)
10. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimers disease and related disorders. Nat Rev Neurosci 8, 663-672. (Pubitemid 47283144)
11. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B (1987) Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol 74, 209-225. (Pubitemid 17142259)
12. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42, 631-639.
13. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimers disease mouse model. Science 316, 750-754. (Pubitemid 46717684)
14. Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA (2009) Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimers disease. J Neurosci 29, 7957-7965.
15. Churcher I (2006) Tau therapeutic strategies for the treatment of Alzheimers disease. Curr Top Med Chem 6, 579-595.
16. Lanzillotta A, Sarnico I, Benarese M, Branca C, Baiguera C, Hutter-Paier B, Windisch M, Spano P, Imbimbo BP, Pizzi M (2010) The-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimers disease. J Mol Neurosci, in press. doi:10.1007/s12031-010-9482-2
17. Samura E, Shoji M, Kawarabayashi T, Sasaki A, Matsubara E, Murakami T, Wuhua X, Tamura S, Ikeda M, Ishiguro K, Saido TC,Westaway D, St George Hyslop P, Harigaya Y, Abe K (2006) Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1. Brain Res 1094, 192-199. (Pubitemid 43927605)
18. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK (2010) Co-occurrence of Alzheimers disease beta-amyloid and tau pathologies at synapses. Neurobiol Aging 31, 1145-1152.
19. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. (Pubitemid 26332733)
20. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimers disease. J Neurosci 25, 8898-8902. (Pubitemid 41384457)
21. Imbimbo BP, Del Giudice E, Colavito D, DArrigo A, Dalle Carbonare M, Villetti G, Facchinetti F, Volta R, Pietrini V, Baroc MF, Serneels L, De Strooper B, Leon A (2007) 1-(3-,4-Dichloro-2-fluoro1,1-biphenyl.-4-yl)- cyclopropanecarboxylic acid (CHF5074), a novel gammasecretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimers disease without causing peripheral toxicity. J Pharmacol Exp Ther 323, 822-830. (Pubitemid 350146064)
22. McArthur RA, Franklin SF, Goodwin A, Oostveen J, Buhl AE (2000) APP overexpressing transgenic mice (Tg2576) are not impaired in the acquisition of an olfactory discrimination task. 30th Annual Meeting Society for Neuroscience, New Orleans, November 4-9. Abstract 275.3.
23. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
24. Fanselow MS (2000) Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res 110, 73-81. (Pubitemid 30236293)
25. Rudy JW, Huff NC, Matus-Amat P (2004) Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev 28, 675-685. (Pubitemid 39535865)
26. Dere E, Huston JP, De Souza, Silva MA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31, 673-704. (Pubitemid 46670336)
27. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, NodaY,Yamaguchi H, Nabeshima T, Saido TC, Iwata N (2006) Neprilysin-sensitive synapseassociated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281, 17941-17951. (Pubitemid 44035593)
28. Mouri A, NodaY, Hara H, Mizoguchi H, Tabira T, Nabeshima T (2007) Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 21, 2135-2148. (Pubitemid 47026449)
29. Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, Quartermain D, Banerjee P, Wisniewski T (2008) Memantine leads to behavioral improvement and amyloid reduction in Alzheimers-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 86, 2784-2791.
30. Zhang L, Xing Y, Ye CF, Ai HX, Wei HF, Li L (2006) Learning-memory deficit with aging in APP transgenic mice of Alzheimers disease and intervention by using tetrahydroxystilbene glucoside. Behav Brain Res 173, 246-254. (Pubitemid 44291828)
31. Balducci C, BeegM, StravalaciM,Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G (2010) Synthetic amyloidbeta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A 107, 2295-2300.
32. Zucker RS, RegehrWG(2002) Short-term synaptic plasticity. Annu Rev Physiol 64, 355-405. (Pubitemid 34259234)
33. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, MobleyWC, Li YM, Sisodia SS, Tanzi RE,Wagner SL (2010) Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimers disease. Neuron 67, 769-780.
34. Selkoe DJ (2008) Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113.
35. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, Braeken D, Callewaert G, Bartic C, DHooge R, Martins IC, Rousseau F, Schymkowitz J, De Strooper B (2010) Neurotoxicity of Alzheimers disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 29, 3408-3420.
36. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869-1879. (Pubitemid 35265544)
37. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX (2006) PKA modulates GSK-3beta-and cdk5-catalyzed phosphorylation of tau in site-and kinasespecific manners. FEBS Lett 580, 6269-6274. (Pubitemid 44666812)
38. Squire LR,Wixted JT, Clark RE (2007) Recognition memory and the medial temporal lobe: a new perspective. Nat Rev Neurosci 8, 872-883. (Pubitemid 350006215)
39. Cooke SF, Bliss TV (2006) Plasticity in the human central nervous system. Brain 129, 1659-1673. (Pubitemid 43999401)
40. Bramham CR (2008) Local protein synthesis, actin dynamics, and LTP consolidation. Curr Opin Neurobiol 18, 524-531.
41. Townsend M, Qu Y, Gray A, Wu Z, Seto T, Hutton M, Shearman MS, Middleton RE (2010) Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimers disease. J Pharmacol Exp Ther 333, 110-119.
42. Li M, Chen L, Lee DH, Yu LC, Zhang Y (2007) The role of intracellular amyloid beta in Alzheimers disease. Prog Neurobiol 83, 131-139. (Pubitemid 47484046)
43. Rebeck GW, Hoe HS, Moussa CE (2010) Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem 285, 7440-7446.
44. Gouras GK, Tsai J, Naslund J,Vincent B, Edgar M, Checler F, Greenfield JP, HaroutunianV, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20. (Pubitemid 30644433)
45. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216. (Pubitemid 33051236)
46. Klein RL, Lin WL, Dickson DW, Lewis J, Hutton M, Duff K, Meyer EM, King MA (2004) Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am J Pathol 164, 347-353. (Pubitemid 38364618)
47. Iqbal K, Grundke-Iqbal I (2006) Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis 9, 219-242. (Pubitemid 44253315)
48. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118, 53-69.
49. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207, 225-236.
50. Glodzik L, de Santi S, Tsui WH, Mosconi L, Zinkowski R, Pirraglia E,Wang HY, Li Y, Rich KE, Zetterberg H, Blennow K, Mehta P, de LeonMJ(2010) Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.12.026
51. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119, 3692-3702.
52. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimers disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)